TSX lower as gold rally takes a breather
Boston Scientific Corp’s stock reached an all-time high of 109.15 USD, marking a significant milestone for the company. With a substantial market capitalization of $160 billion and impressive revenue growth of 21.4% in the last twelve months, this achievement comes on the heels of a strong performance over the past year, during which the stock has seen a 30.8% increase. According to InvestingPro analysis, the stock is currently trading above its Fair Value. The robust growth reflects investor confidence and the company’s solid financial health, with a strong gross profit margin of 68% and healthy cash flows. As Boston Scientific continues to innovate and expand its market presence, the stock’s impressive rise underscores its potential for continued success in the medical devices sector. InvestingPro has identified 15 additional key insights about Boston Scientific’s performance and outlook, available in the comprehensive Pro Research Report.
In other recent news, Elutia Inc. announced it has agreed to sell its EluPro and CanGaroo bioenvelopes to Boston Scientific for $88 million in cash. The transaction is expected to be finalized in the fourth quarter of 2025. Meanwhile, Oppenheimer has upgraded Boston Scientific’s stock rating from Perform to Outperform, citing the company’s strong growth potential and effective merger and acquisition strategy. Oppenheimer set a price target of $125.00, highlighting Boston Scientific’s execution in its electrophysiology franchise as a key factor. Additionally, Boston Scientific disclosed that Jeffrey B. Mirviss, Executive Vice President and President of Peripheral Interventions, will retire on December 1, 2025, but will stay on as a senior advisor until February 27, 2026. In regulatory news, the FDA has identified a potentially high-risk issue with Boston Scientific’s defibrillation leads, which has been linked to patient deaths. The company has informed customers about the issue with certain ENDOTAK RELIANCE Defibrillation leads, as part of the FDA’s Communications Pilot to Enhance the Medical Device Recall Program.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.